UA117353C2 - Форми дозування ензалутаміду - Google Patents

Форми дозування ензалутаміду

Info

Publication number
UA117353C2
UA117353C2 UAA201503119A UAA201503119A UA117353C2 UA 117353 C2 UA117353 C2 UA 117353C2 UA A201503119 A UAA201503119 A UA A201503119A UA A201503119 A UAA201503119 A UA A201503119A UA 117353 C2 UA117353 C2 UA 117353C2
Authority
UA
Ukraine
Prior art keywords
enzalutamide
formulations
disclosure provides
hyperproliferative disorders
provides formulations
Prior art date
Application number
UAA201503119A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дуглас Алан Лоренц
Санжай Конаґурту
Ренді Джей. Уолд
Джейсон Ей. Еверет
Шейла Мец
Ююкі Такаісі
Тосіро Сакаі
Рюсуке Іріє
Сінсуке Оба
Хіроясу Тойота
Кодзі Нісімура
Ацусі Канбаясі
Original Assignee
Медівейшн Простейт Терап'Ютікс Ллс
Астеллас Фарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117353(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Медівейшн Простейт Терап'Ютікс Ллс, Астеллас Фарма Інк. filed Critical Медівейшн Простейт Терап'Ютікс Ллс
Publication of UA117353C2 publication Critical patent/UA117353C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201503119A 2012-09-11 2013-09-11 Форми дозування ензалутаміду UA117353C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11
PCT/US2013/059223 WO2014043208A1 (en) 2012-09-11 2013-09-11 Formulations of enzalutamide

Publications (1)

Publication Number Publication Date
UA117353C2 true UA117353C2 (uk) 2018-07-25

Family

ID=49231627

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201503119A UA117353C2 (uk) 2012-09-11 2013-09-11 Форми дозування ензалутаміду

Country Status (29)

Country Link
US (11) US20140179749A1 (Direct)
EP (6) EP4324527A3 (Direct)
JP (5) JP6404217B2 (Direct)
KR (1) KR102225416B1 (Direct)
CN (2) CN109897004A (Direct)
AU (2) AU2013315619B2 (Direct)
BR (1) BR112015005432B1 (Direct)
CA (1) CA2884795C (Direct)
CY (1) CY1124729T1 (Direct)
DK (1) DK3725778T3 (Direct)
EA (2) EA033374B9 (Direct)
ES (1) ES2892029T3 (Direct)
HK (1) HK1212701A1 (Direct)
HR (1) HRP20211423T1 (Direct)
HU (1) HUE057701T2 (Direct)
IL (1) IL237604B (Direct)
IN (1) IN2015DN02875A (Direct)
LT (1) LT3725778T (Direct)
MX (3) MX363974B (Direct)
PH (1) PH12015500525A1 (Direct)
PL (1) PL3725778T3 (Direct)
PT (1) PT3725778T (Direct)
RS (1) RS62676B1 (Direct)
SI (1) SI3725778T1 (Direct)
SM (1) SMT202100550T1 (Direct)
TW (1) TWI673051B (Direct)
UA (1) UA117353C2 (Direct)
WO (1) WO2014043208A1 (Direct)
ZA (1) ZA201501847B (Direct)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN02875A (Direct) 2012-09-11 2015-09-11 Medivation Prostate Therapeutics Inc
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201508302PA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EA201891397A1 (ru) * 2014-02-05 2019-03-29 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
ES2839128T3 (es) * 2014-12-05 2021-07-05 Aragon Pharmaceuticals Inc Composiciones anticancerosas
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
HRP20241719T1 (hr) 2014-12-05 2025-02-14 Aragon Pharmaceuticals, Inc. Antitumorske smjese
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
WO2016130819A2 (en) * 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
US20180235935A1 (en) 2015-08-12 2018-08-23 Medivation Prostate Therapeutics Llc Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
US11478453B2 (en) 2016-07-21 2022-10-25 Hadasit Medical Research Services And Development Ltd. Treatment for glioblastoma
US20190209469A1 (en) 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
AU2018252153A1 (en) * 2017-04-13 2019-11-07 Jean Paul Remon Xanthohumol-based compositions
RU2019138248A (ru) * 2017-04-28 2021-05-28 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения, содержащая энзалутамид
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
WO2019030691A1 (en) * 2017-08-08 2019-02-14 Dr. Reddy’S Laboratories Limited EXTRUDED COMPOSITIONS OF ENZALUTAMIDE
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
EP3873443A4 (en) * 2018-10-30 2022-07-27 Peloton Therapeutics, Inc. SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS WITH A SUBSTITUTED INDAN AND PROCESSES FOR THEIR PREPARATION AND USE THEREOF
WO2020122244A1 (ja) * 2018-12-14 2020-06-18 富士フイルム株式会社 錠剤及びその製造方法
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
PH12021551657A1 (en) 2019-01-30 2022-05-02 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
BR112021014657A2 (pt) 2019-01-30 2021-09-21 Janssen Pharmaceutica N.V. Métodos para tratar câncer de próstata com base em subtipos moleculares
WO2020229702A1 (en) 2019-05-16 2020-11-19 Leon-Nanodrugs Gmbh Method for producing nanoparticles
US20220249388A1 (en) 2019-05-23 2022-08-11 Helm Ag Nanoparticles comprising enzalutamide
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CA3143111A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
EP4031109A1 (en) * 2019-09-18 2022-07-27 Bristol-Myers Squibb Company Extended release dosage forms for tyk2 inhibitors
CN114585362B (zh) * 2019-09-23 2024-05-07 生态有限公司 治疗制剂及其用途
US20220347102A1 (en) 2019-10-03 2022-11-03 Synthon B.V. Pharmaceutical composition comprising enzalutamide
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
IL297939A (en) * 2020-05-06 2023-01-01 Disruptive Pharma Ab New amorphous active pharmaceutical ingredients
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN114053243B (zh) * 2020-08-05 2024-11-12 齐鲁制药有限公司 一种恩扎卢胺软胶囊及其制备方法
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
EP4635497A3 (en) * 2020-09-09 2025-11-19 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
WO2022061149A1 (en) * 2020-09-18 2022-03-24 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023281528A1 (en) 2021-07-07 2023-01-12 Bdr Pharmaceuticals Int’L Pvt. Ltd "novel oral liquid compositions of enzalutamide and method of manufacturing thereof"
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
CN118251213A (zh) * 2022-01-19 2024-06-25 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
AU2024209240A1 (en) 2023-01-18 2025-07-10 Helm Pharmaceuticals Gmbh Crystalline nanoparticles comprising enzalutamide
WO2024191660A2 (en) * 2023-03-10 2024-09-19 Yale University Compositions and methods for treating steroid hormone-related diseases or disorders
TW202444354A (zh) 2023-03-16 2024-11-16 瑞士商拜耳保健消費品股份有限公司 用於治療荷爾蒙敏感性前列腺癌生化復發患者之雄激素受體拮抗劑
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
EP4520322A1 (en) * 2023-12-06 2025-03-12 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical compositions containing enzalutamide
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法
TR2024004340A1 (tr) * 2024-04-05 2025-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enzalutamidin katı dispersiyonu.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
EP1741424B1 (en) † 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
ATE364374T1 (de) † 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
IN191496B (Direct) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US20010053778A1 (en) 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
CA2439366A1 (en) 2001-02-27 2002-09-06 Julie Cahill Pharmaceutical formulation comprising bicalutamide
SE0103424D0 (sv) † 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CN1787808A (zh) * 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
US20050165185A1 (en) * 2002-04-18 2005-07-28 Spivey Alan C. Preparation of a conjugated molecule and materials for use therein
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
US20050020675A1 (en) * 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
EP1730516A1 (en) 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PL1893196T5 (pl) * 2005-05-13 2015-12-31 Univ California Związek diarylohydantoinowy
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
JP2009502969A (ja) 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
EP2656841B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20100151035A1 (en) 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
CN102083467B (zh) 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
MY160737A (en) 2009-04-03 2017-03-15 Hoffmann La Roche Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
RU2554081C2 (ru) * 2010-02-24 2015-06-27 Медивэйшн Простейт Терапьютикс, Инк. Способ синтеза соединений диарилтиогидантоина и диарилгидантоина
WO2011112558A2 (en) * 2010-03-10 2011-09-15 Abbott Laboratories Solid compositions
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI532732B (zh) 2012-06-07 2016-05-11 亞拉岡製藥公司 雄性激素受體調節劑之晶型
EP2883271B1 (en) * 2012-08-10 2020-07-22 Keyssa, Inc. Dielectric coupling systems for ehf communications
IN2015DN02875A (Direct) 2012-09-11 2015-09-11 Medivation Prostate Therapeutics Inc
JP2015534550A (ja) 2012-09-11 2015-12-03 ドクター レディズ ラボラトリーズ リミテッド エンザルタミドの多形形態およびその調製
WO2014042945A1 (en) 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
RU2019138248A (ru) 2017-04-28 2021-05-28 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения, содержащая энзалутамид
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
US20220347102A1 (en) 2019-10-03 2022-11-03 Synthon B.V. Pharmaceutical composition comprising enzalutamide

Also Published As

Publication number Publication date
PT3725778T (pt) 2021-09-22
US20140378517A1 (en) 2014-12-25
EA201500314A1 (ru) 2015-12-30
MX2021000007A (es) 2021-03-09
EP4450130A3 (en) 2025-01-08
JP2019194262A (ja) 2019-11-07
EP3971167A1 (en) 2022-03-23
CA2884795A1 (en) 2014-03-20
CY1124729T1 (el) 2022-07-22
WO2014043208A1 (en) 2014-03-20
US11839689B2 (en) 2023-12-12
BR112015005432A2 (Direct) 2017-09-05
EP4324527A3 (en) 2024-04-24
US20250049721A1 (en) 2025-02-13
MX2015003140A (es) 2015-12-16
ZA201501847B (en) 2016-01-27
TWI673051B (zh) 2019-10-01
TW201427659A (zh) 2014-07-16
EP4169908A1 (en) 2023-04-26
SMT202100550T1 (it) 2022-01-10
IN2015DN02875A (Direct) 2015-09-11
JP2015527411A (ja) 2015-09-17
CN105358535A (zh) 2016-02-24
EA033374B1 (ru) 2019-10-31
US20230122911A1 (en) 2023-04-20
KR20150082203A (ko) 2015-07-15
AU2013315619A1 (en) 2015-04-30
HUE057701T2 (hu) 2022-05-28
JP2018087206A (ja) 2018-06-07
US20230210778A1 (en) 2023-07-06
PL3725778T3 (pl) 2021-12-20
EP3725778B2 (en) 2026-01-07
AU2013315619B2 (en) 2018-02-08
EP3725778A1 (en) 2020-10-21
US20250090465A1 (en) 2025-03-20
JP2021178871A (ja) 2021-11-18
MX363974B (es) 2019-04-10
EP4450130A2 (en) 2024-10-23
IL237604A0 (en) 2015-04-30
US12447128B2 (en) 2025-10-21
US20170224624A1 (en) 2017-08-10
EP2895463A1 (en) 2015-07-22
US20200060976A1 (en) 2020-02-27
MX2019003984A (es) 2019-08-12
HK1212701A1 (zh) 2016-06-17
US20170027910A1 (en) 2017-02-02
JP6932746B2 (ja) 2021-09-08
AU2018200316A1 (en) 2018-02-08
JP2016204392A (ja) 2016-12-08
LT3725778T (lt) 2021-12-27
EA201991484A1 (ru) 2019-11-29
IL237604B (en) 2021-07-29
US20140100256A1 (en) 2014-04-10
PH12015500525A1 (en) 2015-05-04
CA2884795C (en) 2023-10-17
RS62676B1 (sr) 2021-12-31
US12502357B2 (en) 2025-12-23
CN109897004A (zh) 2019-06-18
US20140179749A1 (en) 2014-06-26
EA033374B9 (ru) 2019-12-18
US20190209476A1 (en) 2019-07-11
CN105358535B (zh) 2019-01-04
JP6404217B2 (ja) 2018-10-10
HRP20211423T1 (hr) 2022-01-21
DK3725778T3 (da) 2021-09-20
ES2892029T3 (es) 2022-02-01
KR102225416B1 (ko) 2021-03-09
BR112015005432B1 (pt) 2023-04-18
EP3725778B1 (en) 2021-08-18
SI3725778T1 (sl) 2022-02-28
EP4324527A2 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
PH12015500525A1 (en) Formulations of enzalutamide
IN2015DN00127A (Direct)
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
IL239453A0 (en) Preparations and methods for treating cancer using bacteria
MY168032A (en) Warm-Cool Beauty Treatment Device
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2014DN11201A (Direct)
IL238177A0 (en) Methods and preparations for the treatment of cancer
ZA201408055B (en) Compositions and methods for the treatment of local pain
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2897689A4 (en) COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
IL239374B (en) Preparations and methods for treating brain tumors
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
MY168958A (en) Intermediates and processes for preparing compounds
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU2012902296A0 (en) Compositions for Therapy and Methods of Treatment
UA80747U (ru) Применение препарата октенисепт как средства для санации полостей суставов при лечении метаэпифизарного остеомиелита